Skip to main content

Table 7 Application of the suggested flourimetric approach for the Estimation of Remdesivir and Levodropropizine in spiked human plasma

From: Green synchronous spectrofluorimetric analysis of remdesivir, the first approved antiviral, with levodropropizine as add-on therapy for covid-19: application in their pharmaceutical dosage form, and spiked human plasma

Remdesivir

Levodropropizine

Added (ng/mL)

Found* (ng/mL)

Recovery%

Added (ng/mL)

Found* (ng/mL)

Recovery%

15

14.58

97.20

15

14.22

94.80

20

19.17

95.85

20

18.57

92.85

50

48.93

97.86

30

27.91

93.03

100

94.87

94.87

60

57.06

95.10

125

118.92

95.14

75

70.35

93.80

Mean ± RSD%

96.18 ± 1.353

Mean ± RSD%

93.92 ± 1.080

  1. * Average of five analyses